tak-187 and Cryptococcosis

tak-187 has been researched along with Cryptococcosis* in 1 studies

Other Studies

1 other study(ies) available for tak-187 and Cryptococcosis

Article	Year
In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans. Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:10 Multiple isolates of Cryptococcus neoformans, including those with fluconazole resistance, were tested to assess the in vitro activity of the new triazole TAK-187. MICs of TAK-187 were at least eightfold lower than those of fluconazole, and fungicidal concentrations for most isolates were 4 microg/ml or less. TAK-187 also was evaluated as intermittent therapy using two dosages in a rabbit model of experimental cryptococcal meningitis. Compared to daily treatment with fluconazole, as little as two doses of TAK-187 given 7 days apart were found to be effective. Plasma and cerebrospinal fluid TAK-187 concentrations were many times higher than MICs and fungicidal concentrations. Based upon its therapeutic efficacy and long half-life in the rabbit model, TAK-187 should be investigated for intermittent dosing in treatment or suppression of cryptococcal infections in humans. Topics: Animals; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Microbial Sensitivity Tests; Rabbits; Triazoles	1998

Article

Year

In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans.

Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:10

Multiple isolates of Cryptococcus neoformans, including those with fluconazole resistance, were tested to assess the in vitro activity of the new triazole TAK-187. MICs of TAK-187 were at least eightfold lower than those of fluconazole, and fungicidal concentrations for most isolates were 4 microg/ml or less. TAK-187 also was evaluated as intermittent therapy using two dosages in a rabbit model of experimental cryptococcal meningitis. Compared to daily treatment with fluconazole, as little as two doses of TAK-187 given 7 days apart were found to be effective. Plasma and cerebrospinal fluid TAK-187 concentrations were many times higher than MICs and fungicidal concentrations. Based upon its therapeutic efficacy and long half-life in the rabbit model, TAK-187 should be investigated for intermittent dosing in treatment or suppression of cryptococcal infections in humans.

Topics: Animals; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Microbial Sensitivity Tests; Rabbits; Triazoles

1998